Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.
Follow KPTI
Karyopharm Therapeutics Inc. (KPTI) Altman Z-score
Karyopharm Therapeutics Inc.'s Altman Z-score for fiscal 2025 is −23.89, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −23.89 | (9.67) |
| FY2024 | −14.22 | (5.37) |
| FY2023 | −8.85 | (4.12) |
| FY2022 | −4.73 | (0.49) |
| FY2021 | −4.23 | (1.36) |
| FY2020 | −2.87 | (0.60) |
| FY2019 | −2.27 | (0.89) |
| FY2018 | −1.38 | (1.02) |
| FY2017 | −0.36 | (7.94) |
| FY2016 | 7.57 | (6.43) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.10 | — | 0.12 | |
| Retained earnings / total assets | (16.23) | — | −22.72 | |
| EBIT / total assets | (0.84) | — | −2.76 | |
| Market value of equity / total liabilities | 0.20 | — | 0.12 | |
| Sales / total assets | 1.35 | — | 1.35 | |
| Altman Z-score | Distress zone | −23.89 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −58.62 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BOLT Bolt Biotherapeutics, Inc. compare | −12.7× |
| SNTI Senti Biosciences, Inc. compare | −13.7× |
| KPTI Karyopharm Therapeutics Inc. | −23.9× |
| APRE Aprea Therapeutics, Inc. compare | −30.1× |
| SNGX Soligenix Inc. compare | −38.9× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | — |
| CNSP CNS Pharmaceuticals, Inc. compare | — |
| ADIL Adial Pharmaceuticals, Inc. compare | — |
| XTLB XTL Biopharmaceuticals Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets